Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
Harold J. Burstein(Dana-Farber Cancer Institute), Jennifer J. Griggs(Michigan Medicine), Christina Lacchetti(Washington Hospital), Nancy E. Davidson(WinnMed), Thomas A. Buchholz(Scripps MD Anderson Cancer Center), Clifford A. Hudis(American Society of Clinical Oncology), Vered Stearns(Johns Hopkins University), Karen A. Gelmon(University of British Columbia), Eric P. Winer(University of Vermont), Sharon H. Giordano(The University of Texas MD Anderson Cancer Center), Alexander J. Solky(BC Cancer Agency), Holly Anderson(BC Cancer Agency)
Cited by 645
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k